Bioventus Inc (BVS)
11.64
+0.59
(+5.34%)
USD |
NASDAQ |
Sep 27, 16:00
11.65
+0.01
(+0.09%)
After-Hours: 20:00
Bioventus SG&A Expense (Annual): 303.88M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 303.88M |
December 31, 2022 | 332.13M |
December 31, 2021 | 254.25M |
December 31, 2020 | 193.08M |
December 31, 2019 | 198.48M |
Date | Value |
---|---|
December 31, 2018 | 191.67M |
December 31, 2015 | 148.44M |
December 31, 2014 | 147.06M |
December 31, 2013 | 150.37M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
193.08M
Minimum
2020
332.13M
Maximum
2022
256.36M
Average
254.25M
Median
2021
SG&A Expense (Annual) Benchmarks
Perspective Therapeutics Inc | 21.06M |
Retractable Technologies Inc | 20.01M |
InfuSystems Holdings Inc | 58.03M |
Xtant Medical Holdings Inc | 64.29M |
Catheter Precision Inc | 17.12M |